"Unlike that drug, known as Epidiolex, the new cannabis formula from drugmaker Vertanical contains THC, the active ingredient in marijuana that gets users high. But levels of the chemical are very low, essentially a microdose compared to what's available in gummies, chocolate bars, and other products sold at marijuana dispensaries in the U.S. The company said patients in the trial didn't show any signs of drug abuse, dependence, or withdrawal."
"The 800-patient study by a German drugmaker is the latest evidence of the therapeutic properties of cannabis, which remains illegal under U.S. federal law even as most states have made it available for medical or recreational use. Health officials in Canada and Europe have previously approved a pharmaceutical-grade form of cannabis for several types of pain, including nerve pain due to multiple sclerosis."
An experimental, pharmaceutical-grade cannabis medication containing microdosed THC significantly reduced lower-back pain in 800 patients. The formula delivers very low levels of THC compared with retail marijuana products, reducing intoxication risk. Participants did not display signs of drug abuse, dependence, or withdrawal. Vertanical seeks approval to treat chronic lower-back pain, a condition with limited long-term drug options. Over-the-counter NSAIDs pose gastrointestinal risks for extended use, and opioids carry addiction concerns. Regulatory precedents include approvals of cannabinoid medicines in Canada, Europe, and an FDA-approved CBD drug for rare pediatric seizures. Chronic pain remains a common reason for medical cannabis use.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]